TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01916421

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)
Study: NCT01318746

Intervention type: PROCEDURE
Intervention: Blood withdrawal
Description: blood withdrawal every 2 hours during 24 hours

Intervention type: PROCEDURE
Intervention: Blood withdrawal
Description: blood withdrawal every 2 hours during 24 hours
Study: NCT03990779

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiographic examination before and after cardiopulmonary bypass
Study: NCT02130700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-464: given orally twice daily in 28-day cycles
Description: Oral VT-464 given twice daily, in continuous 28-day cycles at the recommended Phase 2 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-464: given orally twice daily in 28-day cycles
Description: Oral VT-464 given twice daily, in continuous 28-day cycles at the recommended Phase 2 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-464: given orally once daily in 28-day cycles
Description: Oral VT-464 given once daily, in continuous 28-day cycles at the recommended Phase 2 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-464: given orally once daily in 28-day cycles
Description: Oral VT-464 given once daily, in continuous 28-day cycles at the recommended Phase 2 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-464: given orally once daily in 28-day cycles
Description: Oral VT-464 given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
Study: NCT01927107

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics mixture
Description: Comparison of probiotic mixture in addition to standard diet therapy vs. standart diet therapy
Study: NCT01692522

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: visualized blind intubation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intubation
Description: visualized blind intubation
Study: NCT00456261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: pemetrexed 500 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: pemetrexed 500 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1500 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab 10mg/kg bevacizumab 15mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab 10mg/kg bevacizumab 15mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC=5
Study: NCT02094950

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Study: NCT03280745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl by infusion pump over 60 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline
Description: At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
Study: NCT03471806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food reward at baseline
Description: Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at baseline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food reward at baseline
Description: Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at baseline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food reward after treatment
Description: Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at the end of inpatient treatment.
Study: NCT01465256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin hold for a certain period of time in the patients who take aspirin for the primary prevention of vascular disease,
Study: NCT04394663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose oral omeprazole
Description: Local made oral omeprazole 40 mg twice daily will be prescribed for 72 hours after randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard IV PPI
Description: Pantoprazole 8mg/hour IV continuous drip will be prescribed for 72 hours after randomization
Study: NCT00693615

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-517 HPV-16/18 VLP AS04 vaccine
Description: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-517 HPV-16/18 VLP vaccine with Al(OH)3
Description: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-517 HPV-16/18 VLP vaccine without adjuvant
Description: IM injection
Study: NCT00671047

Intervention type: OTHER
Intervention: non-interventional
Description: SLE nature history observational
Study: NCT03884309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Hydrolyzed Protein Infant Formula
Description: fed ad libitum
Study: NCT04500678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg Extended Release (ER) qd increasing to 1000 mg ER qd at week 4 and continued to week 48.
Study: NCT00408187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: voclosporin
Description: voclosporin 0.4 mg/kg po BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporin
Description: ciclosporin 1.5 mg/kg po BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01461473

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive Airway Pressure (PAP)
Description: Participants randomized to the Positive Airway Pressure treatment group received adequate Positive Airway Pressure (PAP) pressure therapy by a PAP titration study and used the device for 6 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oral Appliance (OA)
Description: Participants randomized to the Oral Appliance treatment group received a dental evaluation to determine the optimal setting for the Oral Appliance (OA), and used the appliance for 6 months.
Study: NCT00871364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VENLAFAXINE TABLETS 50 mg , single dose
Description: A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effexor® Tablets equivalent to 50 mg venlafaxine
Description: B: Active comparator Subjects received Wyeth Pharmaceuticals Inc. formulated products under fed conditions
Study: NCT04912414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Family Therapy (BFT)
Description: Patients transferred to the hospital for the treatment of psychosomatic symptoms was randomized (1:1) to receive either Brief Family Therapy (BFT) or a control treatment. Some participants randomized to the BFT arm receive a combination of chemotherapy and BFT and others receive only BFT. BFT comprises 10 sessions using a generic model of problem formation and resolution. This psychotherapy is useful for treating individual, couple, and family problems. Its broad applicability is based on its view that the client's complaint is the problem, not a symptom of something else BFT views behavior, especially a client's problematic behavior, as a function of interaction with other people. After randomization, all participants were asked to complete questionnaires about their psychosomatic symptoms and health at baseline, at the end of the intervention (at 4 months).
Study: NCT01556932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABH gel
Description: Given topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABH gel
Description: Given topically

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given topically

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given topically
Study: NCT03116009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Screening for diabetes with 1-hour GCT and HbA1
Description: They will receive 50gm oral glucose tolerance test before 20 weeks and if abnormal, they will do the diagnostic test with 100gm OGTT with HbA1C.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Screening for diabetes with 1-hour GCT and HbA1
Description: They will receive 50gm oral glucose tolerance test before 20 weeks and if abnormal, they will do the diagnostic test with 100gm OGTT with HbA1C.
Study: NCT01981811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ingestible Event Marker (IEM)
Study: NCT01006590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 5 mg, oral tablet, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg, oral tablet, 1 or 2 additional tablets per day added to background therapy
Study: NCT00057005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAMPATH-1H
Description: Day-8 through Day-6 according to institutional SOPs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD45
Description: Day-5 400 μg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: day-7 through day-5 3000 mg/m2 q 12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day-7 through Day-6 45 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Days -7 and -6 45 mg/kg divided into 5 doses

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 150 cGy x 2 (5/6 matched related) 180 cGy x 2 (5/6 matched unrelated)
Study: NCT00487097

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eicosapentanoic acid, docosahexaenoic acid
Description: Enteral nutrition formula enriched with Eicosapentanoic acid, docosahexaenoic acid
Study: NCT01742754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal microbiota transplantation by colonoscopic administration of 300cc of fecal slurry from healthy donor to the right colon.
Study: NCT03492905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behaviour Therapy (iCBT)
Description: Guided self-help for 7 weeks. Contact with therapist 2 times per week.
Study: NCT02598778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate (0.12%)
Description: 30 second oral rinse of 10mL of solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride (0.05%)
Description: 30 second oral rinse of 10mL of solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Paraffin wax chewing gum (sugar-free)
Description: Approximately two minutes of chew time
Study: NCT04624945

Intervention type: DIAGNOSTIC_TEST
Intervention: APTT CWA (Activated partial thromboplastin time clot waveform analysis), Procalcitonin and Serological/Inflammatory markers (KL-6, SPA, MIG, Presepsin)
Description: Primary Aim: To validate the use of APTT CWA (Activated partial thromboplastin time clot waveform analysis) and ICIS (Intensive Care Infection Score), as early sepsis markers for neurosurgical ICU patients suffering subarachnoid haemorrhage, traumatic brain injury and other intracranial haemorrhages.~Secondary Aim: To examine the evolution of CWA, immuno-parameters (KL-6, SP-A, MIG, presepsin) and various WBC (white blood cell count) activation markers over the time in relation to diagnosis of sepsis, development of positive blood cultures and mortality or recovery. Blood parameter measurements using a 3-part and 5-part differential analyser will be performed. KL-6, SP-A, MIG, presepsin are serum biomarkers - MIG (Monokine induced by gamma interferon), SP-A (Surfactant protein A), KL-6 (Krebs von den Lungen 6).
Study: NCT02586415

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular Thrombectomy
Description: Patients will be treated with thrombectomy devices (stent-retrievers) and/or suction thrombectomy systems currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke following the published instructions for use for these devices. These devices will be used between 6 and 16 hours following symptom onset in DEFUSE 3 based on an FDA IDE. The devices which will be used are the Trevo Retriever, the Solitaire Revascularization Device and the Penumbra system thrombectomy system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trevo Retriever
Description: Trevo Retriever is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Solitaire™ FR Revascularization Device
Description: Solitaire™ FR Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Penumbra thrombectomy system
Description: Penumbra thrombectomy system is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure. The Penumbra System includes:~• Penumbra Aspiration Pump (1115V) Penumbra System 054 Penumbra System MAX Penumbra System 110 Aspiration Tubing Penumbra System \[026, 032, 041\] Penumbra System Separator Flex \[026, 032, 041, 054\] Penumbra Pump MAX Penumbra System Reperfusion Catheter ACE64 \& ACE68

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Covidien MindFrame Capture Revascularization Device
Description: Covidien MindFrame Capture Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
Study: NCT00443209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telcagepant 300 mg soft gel capsules
Description: One capsule taken orally at onset of migraine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telcagepant 280 mg tablets
Description: One tablet taken orally at onset of migraine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rizatriptan 10 mg tablets
Description: One tablet taken orally at onset of migraine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to telcagepant capsules
Description: One capsule taken orally at onset of migraine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to telcagepant tablets
Description: One tablet taken orally at onset of migraine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to rizatriptan tablets
Description: One tablet taken orally at onset of migraine
Study: NCT01206699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticoid (altim® 1.5 ml)
Description: Active arm : anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with corticoid (altim® 1.5 ml)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: physiological solution (1.5 ml)
Description: Control arm: anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with physiological solution (1.5 ml)
Study: NCT04563299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive a sham dilation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate
Description: All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week).
Study: NCT04457817

Intervention type: DEVICE
Intervention: CRI
Description: Monitoring via CRI
Study: NCT02342145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab,
Description: Basiliximab was used 10mg each time on 0d(after transplantation) and +4 d .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine A
Description: Specifically cyclosporine A was used by intravenous drip infusion on 2mg/kg dosage from -1d and change to 5mg/kg twice oral when gastrointestinal function recovers. The blood concentrations of cyclosporine A was maintained 150-250ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A
Description: Specifically cyclosporine A was used by intravenous drip infusion on 2mg/kg dosage from -1d and change to 5mg/kg twice oral when gastrointestinal function recovers. The blood concentrations of cyclosporine A was maintained 150-250ng/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate was used 15mg/m2 on +1d and 10mg/m2 on +3,+6,+11d by intravenous for prevention of graft-versus-host-disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate was used 15mg/m2 on +1d and 10mg/m2 on +3,+6,+11d by intravenous for prevention of graft-versus-host-disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil was used 0.25g qd from 0d to 3 months for prevention of graft-versus-host-disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil was used 0.25g qd from 0d to 3 months for prevention of graft-versus-host-disease.
Study: NCT03235362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1705
Description: Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1705
Description: Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days in each period.
Study: NCT02598778

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Deionized water
Description: 30 second oral rinse of 10mL of solution
Study: NCT02066597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Description: Within 96 hours of enrolment, patients will be treated with a single session of PMT using an AngioJet catheter without adjuvant thrombolysis . Venous access will be obtained at the popliteal vein in all patients with a 5-F sheath through which all subsequent venography procedures will be performed. The AngioJet catheter will then be passed over the guide wire and moved from proximal to distal to remove thrombus. Completion venography will be performed through the sheath in all patients. After the completion of the procedure patients are expected to remain in hospital for no more than six hours (1 hour in post-anaesthesia care unit followed by transfer to the surgical daycare unit from where they will be discharged).
Study: NCT00696995

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
Study: NCT03421275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: anesthetic used as analgetic in subanesthetic doses given intranasally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: intravenous fentanyl given intranasally
Study: NCT03235362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1705
Description: Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1705
Description: Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1705
Description: Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR1705
Description: Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days in each period.
Study: NCT03421275

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal
Description: intravenous saline given intranasally as placebo
Study: NCT02958410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD30-CAR-transduced T cells
Description: The first 3 enrolled patients will receive autologous-derived CD30-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.